Eli Lilly and Company (NYSE:LLY) is Zurcher Kantonalbank Zurich Cantonalbank’s 10th Largest Position

Zurcher Kantonalbank Zurich Cantonalbank lessened its stake in Eli Lilly and Company (NYSE:LLY) by 8.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 522,150 shares of the company’s stock after selling 46,274 shares during the quarter. Eli Lilly and Company accounts for approximately 1.2% of Zurcher Kantonalbank Zurich Cantonalbank’s holdings, making the stock its 10th biggest position. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 0.06% of Eli Lilly and Company worth $304,372,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Lipe & Dalton bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $26,000. Thompson Investment Management Inc. bought a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at about $27,000. Retirement Group LLC grew its stake in shares of Eli Lilly and Company by 159.1% during the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after purchasing an additional 35 shares during the period. Legacy Financial Group LLC bought a new position in shares of Eli Lilly and Company during the 3rd quarter valued at approximately $35,000. Finally, Optiver Holding B.V. bought a new position in shares of Eli Lilly and Company during the 3rd quarter valued at approximately $36,000. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.13% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of recent research reports. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. The Goldman Sachs Group boosted their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Bank of America boosted their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Finally, DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a report on Wednesday, February 21st. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Stock Down 0.6 %

Shares of NYSE LLY traded down $4.21 during mid-day trading on Tuesday, reaching $746.56. 2,568,597 shares of the company were exchanged, compared to its average volume of 3,085,273. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The stock has a market cap of $709.35 billion, a price-to-earnings ratio of 128.34, a P/E/G ratio of 1.65 and a beta of 0.34. Eli Lilly and Company has a 1 year low of $367.35 and a 1 year high of $800.78. The firm has a 50-day moving average of $762.68 and a 200 day moving average of $655.54.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same period in the prior year, the business posted $2.09 EPS. The firm’s quarterly revenue was up 28.1% on a year-over-year basis. On average, research analysts expect that Eli Lilly and Company will post 12.46 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.